Did you know?

Nearly 10% of new cancer cases diagnosed each year in the U.S. are hematologic malignancies, including leukemia, lymphoma and myeloma.

#AML remains a serious blood cancer with significant unmet need, underscoring the importance of continued innovation.

$SNTI

At Senti, our mission is to create a new generation of smarter medicines designed to outsmart complex diseases.

Through innovative Gene Circuit technology, we are advancing novel approaches with the potential to transform patient care.

$SNTI #AML #Leukemia #Oncology

#DidYouSee - BioTuesdays featured our CEO, Timothy Lu!

He discusses how the Company's Gene Circuit platform is advancing next-generation cell and gene therapies.

Read More: bit.ly/4f7zCjo

$SNTI #CellandGeneTherapy #Cancer

#StayInTheLoop

Get the latest updates from Senti Bio delivered straight to your inbox.

Sign up today: bit.ly/3ZVnb39

$SNTI #AML #Leukemia #Oncology

At Senti Bio, we are advancing intelligent Gene Circuits designed for next-generation cell and gene therapies with a focus on oncology.

Guided by our values: Be Bold, Better Together, Build to Last. We are working to tackle hard-to-treat diseases.

$SNTI #Leukemia #AML #Oncology

AML is the most common type of acute leukemia in adults, accounting for 80% to 85% of cases, with a 5-year survival rate of 31.7% in the United States at diagnosis.

$SNTI #AML #Leukemia #Oncology

Don’t miss the latest from Senti Biosciences!

Subscribe to email alerts for updates on our pipeline, research, and company news: bit.ly/3ZVnb39

$SNTI #Oncology #Leukemia

Our CEO, Tim Lu, highlighted a transformational milestone as positive FDA RMAT feedback advances SENTI-202 toward a potential registrational study in relapsed/refractory AML.

Read more here: bit.ly/4wv4mCD
$SNTI #AML #Oncology #CellTherapy

Our Chief Medical Officer, Kanya Rajangam, highlighted strong momentum for SENTI-202, supported by encouraging clinical activity, a favorable safety profile, and advancements in donor selection.

Learn more: bit.ly/4wv4mCD
$SNTI

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

bit.ly/4wv4mCD
$SNTI

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

bit.ly/4dpqGFi
$SNTI #CellTherapy #Oncology #AML

Senti Bio was founded to build a new generation of smarter medicines designed to address complex diseases using novel and unprecedented approaches.

$SNTI #AML #Oncology

This #WorldDNADay, we recognize the power of genetic science in advancing new approaches to cancer treatment.

At Senti Bio, we’re leveraging gene circuits to drive innovation in cell and gene therapy.

$SNTI #Oncology #AML

On #AMLWorldAwarenessDay, we recognize the urgency to advance research and bring forward new therapies. Because behind every diagnosis is a life, a family, and a future.

We acknowledge the importance of continuing to push science forward to create new possibilities for patients.

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

bit.ly/3QgGnqb
$SNTI #CellTherapy #Oncology #AML

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

bit.ly/4cgkRue
$SNTI #CellTherapy #Oncology #AML

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

bit.ly/3PBFecv
$SNTI #CellTherapy #Oncology #AML

Founded to develop a new generation of smarter medicines, Senti Biosciences is advancing innovative approaches to outsmart complex diseases and redefine what’s possible in medicine.

$SNTI #Oncology #AML

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

bit.ly/4t6OzHS
$SNTI #CellTherapy #Oncology #AML

Want to hear about our latest progress?
Stay in the loop by signing up for our email alerts.
bit.ly/3ZVnb39

$SNTI #Oncology #AML

Senti Biosciences is heading to the Leerink Global Healthcare Conference, March 8-11 in Miami Beach, FL!

Join us for our presentation on March 9th from 2:20–2:50 PM as we share updates on our cell engineering platform and pipeline.

Don't Miss It: bit.ly/3MIYyDL

$SNTI

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 2:20 PM ET

bit.ly/4ubbJ1a
$SNTI #CellTherapy #Oncology #AML

Senti Bio is a clinical-stage company advancing a new generation of cell and gene therapies for patients living with incurable diseases.

$SNTI #Oncology #AML

Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference on Monday, March 2nd at 3:10 PM ET

bit.ly/4aPOAs2
$SNTI #CellTherapy #Oncology #AML

Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development

bit.ly/4rZXiLe
#CellTherapy #Oncology #AML

Stay up to date on our latest news, clinical progress and company updates.

Sign up for email alerts: bit.ly/3ZVnb39

$SNTI #Oncology #AML

#DidYouKnow

Each year, more than 20,000 people in the U.S. are diagnosed with #AML, and many face relapse or poor outcomes within the first year.

This highlights a significant unmet need for new, innovative treatment approaches.

$SNTI #Oncology

Thank you, David Wild of InVivo, for taking the time to explore and cover our success in addressing a central challenge in oncology, and for highlighting our clinical and regulatory milestones in advancing a first-in-class AML therapy.

Find out more here: bit.ly/4kyiJAE

Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

bit.ly/4kABuDI
$SNTI #CellTherapy #Oncology #AML

February is National Cancer Prevention Month.

Senti Bio remains focused on advancing next-generation science to help change the future of cancer care.

$SNTI #Oncology #AML

Senti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026 on Tuesday, February 10, 2026, from 10:30 AM to 10:40 AM local time, in Track 1 at the Regent Ballroom (Level 3).

bit.ly/4tkRRZ4
#CellTherapy #Oncology #AML

Nearly 10% of new cancer cases in the U.S. are blood cancers like leukemia, lymphoma, and myeloma. Behind every statistic is a person, a family, a story.

At $SNTI, we’re working to bring them new hope through smarter, more precise cell therapies.
#AML #Leukemia #Oncology

An article titled “Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial” was recently published by GeneOnline, highlighting the FDA’s RMAT designation for SENTI-202 and encouraging early clinical results in AML.

🔗: bit.ly/4aLcQ03

$SNTI has been selected as one of 10 overseas companies named to the Japan Entry Acceleration Program in the field of regenerative medicine.

This selection reflects our innovation and expanding global footprint in cell and gene therapy.

Learn more: bit.ly/45XgRLD

#InCaseYouMissedIt: Updated clinical results from SENTI-202 were discussed during Senti Biosciences’ recent webcast following presentations at the ASH Annual Meeting & Exposition. Catch up on the key insights and data from the discussion.

Watch the replay//bit.ly/4pTOOV3

Senti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT Designation

bit.ly/4qk5yoS
$SNTI #CellTherapy #Oncology #AML

Founded on Smart Science. Driven by Strong Leadership.

Relentlessly developing differentiated cancer therapeutics designed to outsmart the toughest diseases.

$SNTI #Oncology #AML

Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference on Tuesday, January 13, 2026 at 8:00 AM PST

bit.ly/49h6epi
$SNTI #CellTherapy #Oncology #AML

Senti Biosciences will be in San Francisco, CA, January 12–15 during the J.P. Morgan Healthcare Conference.

To schedule a meeting, please contact snti@jtcir.com.

$SNTI #Oncology #AML

In 2026, we remain committed to becoming an industry leader in the cell and gene therapy landscape by advancing our unique approach to developing intelligent Gene Circuits for next-generation cell and gene therapies, with a focus on oncological diseases.

$SNTI #Oncology #AML

Happy Holidays from all of at us Senti Bio to you and your families! Wishing you a joyful season.

#HappyHolidays

We strive to outsmart complex diseases by developing more intelligent medicines. We are better together and always learning as we work to advance the future of oncology.

$SNTI #Oncology #AML #Leukemia

Almost 10% of new cancer cases in the U.S. each year are blood cancers, including leukemia, lymphoma and myeloma.

We are dedicated to developing innovative therapies to help transform outcomes for patients with these hematologic malignancies.

$SNTI #CellTherapy #AML

Senti Biosciences Announces New Employment Inducement Grants

bit.ly/3KT2aCa
$SNTI

At $SNTI, we are designing gene circuits to power the next generation of cell and gene therapies, working to push the boundaries of what is possible in synthetic biology.

#CellTherapy #AML #Oncology

Dr. Kanya Rajangam, Chief Medical Officer, emphasized that the encouraging SENTI-202 data support advancement into pivotal studies and exploration across additional patient populations, enabled by recent RMAT and Orphan Drug Designations.

bit.ly/3XFf7ST

$SNTI #ASH2025

Dr. Farhad Ravandi of MD Anderson Cancer Center discusses our #ASH25 data on @VJHemOnc and why our success targeting CD33 and FLT3, which is expressed highly on AML blasts is so significant in meeting significant unmet needs.

Read the story: bit.ly/4961jXS
$SNTI

Thank you @GeneOnlineNews for the for the fantastic discussion about #SENTI-202 data presented at #ASH25.

We appreciate the spotlight on the data, showing deep, durable responses in relapsed/refractory AML.

Read the article: bit.ly/4aLcQ03

You can now access our ASH poster presentation on our website:
Correlative data from the ongoing Phase 1 study of SENTI-202, showcasing its selective, logic-gated design targeting CD33 and/or FLT3 in AML.

View it here: bit.ly/4pR10FY

$SNTI #CellTherapy #GeneCircuits

Our recently delivered oral presentation is now available on our website:
Promising results from an ongoing Phase I study of SENTI-202, a first-in-class Logic Gated CD33/FLT3 cell therapy for R/R AML.

Access it here: bit.ly/4jKTFFb

$SNTI #ASH25 #AML #CellTherapy

Dr. Timothy Lu, CEO, highlighted how Logic Gated cell therapies are designed to precisely target cancer while protecting healthy tissue, positioning SENTI-202 as a potentially transformative therapy for AML.

Check it out here: bit.ly/3XFf7ST

$SNTI #ASH2025

Thank you very much to Dr. Jonathan D. Grinstein for your excellent article in @Inside_PM about how Senti Bio's Logic Gates are transforming the treatment landscape for cancer patients.

Learn more here: bit.ly/4940X3Z

$SNTI #BloodCancer #AcuteMyeloidLeukemia #R/RAML

#InCaseYouMissedIt: We hosted a live webcast sharing updated clinical results from SENTI-202 featured at the ASH Annual Meeting & Exposition. Catch up on the latest data and key insights.

Watch the replay: bit.ly/4pTOOV3

$SNTI #AML #Oncology

Dr. Nosha Farhadfar noted that SENTI-202 is demonstrating deep, durable responses and a favorable safety profile in R/R AML, underscoring its potential to selectively target AML cells while preserving healthy ones.

bit.ly/3XFf7ST
$SNTI #AML #ASH2025

#DidYouSee: We announced new data from our ongoing multinational, multicenter clinical trial of SENTI-202, a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy being studied in patients with relapsed or refractory #AcuteMyeloidLeukemia.

bit.ly/3XFf7ST

#StartingSoon

Senti Bio will be hosting a live webcast beginning at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting & Exposition.

Stay tuned — we’re almost live.

bit.ly/4pTOOV3
$SNTI #AML #Oncology

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile

bit.ly/3XFf7ST
$SNTI #AML

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

bit.ly/4pX5omL
$SNTI #CellTherapy #Oncology #AML

#TuneInTomorrow

Senti Bio will be hosting a live webcast tomorrow at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting & Exposition.

bit.ly/4pTOOV3
$SNTI #AML #Oncology

We will be featured at #ASH2025 with an oral presentation on December 8 at 5:45 PM in Valencia Room W415BC.

Title: Promising results from an ongoing Phase I study of SENTI-202, a first-in-class Logic Gated CD33/FLT3 cell therapy for R/R AML

Presenter: Timothy Lu, CEO

#MarkYourCalendars

Senti Bio will be hosting a live webcast on December 9 at 8:00 AM ET to discuss updated clinical results from SENTI-202 being presented at the ASH Annual Meeting & Exposition.

You won’t want to miss it.

bit.ly/4pTOOV3
$SNTI #AML #Oncology

We’re heading to Orlando for the ASH Annual Meeting & Exposition (Dec 6–9)!

Excited to connect with the hematology community and share our progress in advancing smarter cell and gene therapies.

$SNTI #AML #Oncology

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Society of Hematology (ASH) Annual Meeting 2025 on Tuesday, December 9th at 8:00 AM ET

bit.ly/4iCdIWA
$SNTI #CellTherapy #Oncology #AML

At Senti Biosciences, we’re powered by industry-leading management.

Learn more about the $SNTI team here: bit.ly/4jIdBIZ

#CellTherapy #Oncology #AML

Behind every breakthrough is a patient, a family, a story.

Our mission goes beyond science, it’s about giving hope to those fighting the toughest diseases.

$SNTI #Oncology #Leukemia #CellTherapy

Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

bit.ly/47UaCIR
$SNTI #CellTherapy #AML #Oncology

Senti Bio was featured in GEN’s “Biopharma Embraces Synthetic Biology” by Tiffany Yesavage, PhD — highlighting SENTI-202 and how our gene circuit technology is advancing next-generation programmable cell therapies.

Read more: bit.ly/47Nb8br

$SNTI #CellTherapy #AML

Founded on smart science. Driven by strong leadership. We’re relentlessly developing next-generation cancer therapies designed to outsmart the toughest diseases.

$SNTI #CellTherapy #Leukemia #Oncology

At Senti Biosciences, we’re engineering cells with DNA-encoded programs that can sense, decide, and respond to disease, paving the way for a new era of smarter, more precise therapies.

$SNTI #AML #Leukemia #Oncology

Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025

bit.ly/437qPZB
$SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

#DidYouKnow: Nearly 1 in 10 new cancer cases in the U.S. each year are blood cancers such as #Leukemia, #Lymphoma and #Myeloma.

At $SNTI, we’re working to change outcomes with smarter, more precise therapies.

#CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

At Senti Bio, we’re committed to developing differentiated cancer therapies designed to outsmart the toughest diseases.

$SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Senti is pleased to be attending Chardan’s 9th Annual Genetic Medicines Conference in New York on October 21!

Live webcast presentation on today, October 21st at 11:35 AM ET: bit.ly/4qqMo1o

$SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference on Tuesday, October 21st at 11:35 AM ET

bit.ly/3IQqDqN
$SNTI #CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Thank you to #BioJapan2025 for the opportunity to present in Yokohama!

Our CEO & Co-Founder, Dr. Timothy Lu, shared insights on Senti’s synthetic biology platform and our progress advancing next-generation cell and gene therapies.

$SNTI #CellTherapy #AcuteMyeloidLeukemia

Each year, about 20,800 people in the U.S. are diagnosed with #AML. Sadly, nearly 60% face relapse or death within the first year. At $SNTI Bio, we’re working to change this reality through innovative cell and gene therapies.

#CellTherapy #AML #Oncology #AcuteMyeloidLeukemia

Senti Bio to Present at BioJapan on Thursday, October 9th at 11:30 AM JST

bit.ly/4mTYr3X
$SNTI #CellTherapy #AML #CARNK

#InCaseYouMissedIt: $SNTI joined #VirtualInvestor, where Dr. Kanya Rajangam, Head of R&D, shared insights on the recommended Phase 2 dose of SENTI-202, our potential first-in-class CAR-NK therapy for #AML and other blood cancers.

Watch the segment: vimeo.com/1109325415/9f2…

We are excited to announce that Dr. Kanya Rajangam, President, Head of Research & Development, and Chief Medical Officer, will be presenting at the MedInvest Biotech & Pharma Investor Conference taking place September 24–25 in Palo Alto, CA.

$SNTI #CellTherapy #AML #CARNK

Senti Bio to Present at the MedInvest Biotech & Pharma Conference on Wednesday, September 24th at 9:55 AM PT

bit.ly/47PEmrY
$SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia

Tomorrow at 9:05 AM PT, Vice President of Research Brian Garrison will present on Next-Generation Personalized Cell Therapy Engineering Innovations at Advanced Therapies Xchange in San Francisco, CA.

$SNTI #AML #CellTherapy

Halfway through Blood Cancer Awareness Month, we’re reminded that behind every statistic is a person — a patient, a caregiver, a loved one — facing the challenges of blood cancer. Let’s continue to raise awareness, share knowledge and stand together in hope.

$SNTI #CellTherapy

🚨 Starting Soon at 2:00 PM ET! Don’t miss #SNTI CEO Tim Lu live at the H.C. Wainwright 27th Annual Global Investment Conference in New York City!

Can’t attend in person? Access the webcast here: bit.ly/4mK46dE

$SNTI #CellTherapy #AML #CARNK #AcuteMyeloidLeukemia

Exciting news! $SNTI is set to present at the H.C. Wainwright 27th Annual Global Investment Conference.

Don’t miss CEO Tim Lu live in New York City on September 8 at 2:00 PM ET!

bit.ly/4mK46dE

#CellTherapy #AML #CARNK #AcuteMyeloidLeukemia

September marks Blood Cancer Awareness Month — a time to stand with patients, survivors and families, and to raise awareness of the urgent need for better detection, treatment, and support. Together, we can make a difference.

Learn more//bit.ly/3TfRvSU

$SNTI #AML

September marks Blood Cancer Awareness Month — a time to stand with patients, survivors and families, and to raise awareness of the urgent need for better detection, treatment, and support. Together, we can make a difference.

Learn more//bit.ly/3TfRvSU

$SNTI #AML